淋巴瘤试验中组织要求提高可能排除高危或预后较差患者
该观察性研究比较了新诊断弥漫大B细胞淋巴瘤和原发纵隔大B细胞淋巴瘤患者接受切除活检与空芯针活检的特征、结局及诊断组织充分性。1061例患者中532例(49.8%)接受切除活检,529例(50.1%)接受空芯针活检;空芯针活检组晚期疾病、国际预后指数≥3及组织不足以进行分子分析的比例显著更高,5年无事件生存率和总生存率均显著更差。
要点
- 空芯针活检组晚期疾病、国际预后指数≥3及组织不足的比例显著高于切除活检组。
- 空芯针活检组5年无事件生存率为56.9%,切除活检组为67.6%,风险比为0.76。
- 空芯针活检组5年总生存率为69.2%,切除活检组为76.4%,风险比为0.8。
核心结论
- 接受空芯针活检的患者具有不良风险特征且一线化学免疫治疗结局较差,更可能组织不足用于分子分析,可能不符合生物标志物驱动临床试验的组织要求。
- 生物标志物驱动临床试验日益增加的组织要求可能导致需要新药的高危弥漫大B细胞淋巴瘤患者被排除。
研究设计与样本
- 观察性研究,纳入新诊断弥漫大B细胞淋巴瘤和原发纵隔大B细胞淋巴瘤患者,比较接受切除活检与空芯针活检者的特征、结局和诊断组织充分性。
- 共1061例患者,其中532例(49.8%)接受切除活检,529例(50.1%)接受空芯针活检。
主要发现
- 空芯针活检组晚期疾病、国际预后指数≥3及组织不足以进行分子分析的比例显著高于切除活检组。
- 空芯针活检组5年无事件生存率为56.9%,切除活检组为67.6%(风险比0.76,95%置信区间0.6-0.9,P<.001)。
- 空芯针活检组5年总生存率为69.2%,切除活检组为76.4%(风险比0.8,95%置信区间0.6-0.9,P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An enhanced understanding of the molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) has opened the door to clinical trials evaluating novel agents with subtype-specific activity. It is an emerging question whether core needle biopsies (CNB) can adequately meet the increasing tissue requirements of these clinical trials. This can potentially lead to selective enrollment of patients who can undergo excisional biopsy (EB). It is also important to know whether patients who can undergo extensive diagnostic work up differ in their disease characteristics and outcomes from those who cannot. In this observational study, we describe the characteristics, outcomes, and adequacy of diagnostic tissue in patients with newly diagnosed DLBCL and primary mediastinal large B-cell lymphoma who underwent EB vs CNB. Of the 1061 patients, 532 (49.8%) underwent EB and 529 (50.1%) underwent CNB. A significantly higher proportion of patients with CNB had advanced stage disease, an international prognostic index of ≥3, and inadequate tissue for molecular analyses. Patients with CNB had significantly worse 5-year event-free survival (67.6% vs 56.9%; hazard ratio [HR], 0.76; confidence interval [CI]95, 0.6-0.9, P < .001) and 5-year overall survival (76.4% vs 69.2%; HR, 0.8; CI95, 0.6-0.9, P < .001). Thus, patients who underwent CNB have poor-risk features and inferior outcomes on frontline chemoimmunotherapy, are more likely to have inadequate tissue for molecular analyses, and might not meet the tissue requirements of biomarker-driven clinical trials. Thus, the increasing tissue requirements of biomarker-driven clinical trials may result in the exclusion of patients with high-risk DLBCL who need novel agents.
引用
- Desai SH, Mwangi R, Ng WL, et al. Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis. Blood Adv. 2022. PMID: 36170803. doi:10.1182/bloodadvances.2022007569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。